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Regulation of cell growth requires extensive coordination of several processes including transcription, ribosome biogen-
esis, translation, nutrient metabolism, and autophagy. In yeast, the protein kinases Target of Rapamycin (TOR) and
protein kinase A (PKA) regulate these processes and are thereby the main activators of cell growth in response to
nutrients. How TOR, PKA, and their corresponding signaling pathways are coordinated to control the same cellular
processes is not understood. Quantitative analysis of the rapamycin-sensitive phosphoproteome combined with targeted
analysis of PKA substrates suggests that TOR complex 1 (TORC1) activates PKA but only toward a subset of substrates.
Furthermore, we show that TORC1 signaling impinges on BCY1, the negative regulatory subunit of PKA. Inhibition of
TORC1 with rapamycin leads to BCY1 phosphorylation on several sites including T129. Phosphorylation of BCY1 T129
results in BCY1 activation and inhibition of PKA. TORC1 inhibits BCY1 T129 phosphorylation by phosphorylating and
activating the S6K homolog SCH9 that in turn inhibits the MAP kinase MPK1. MPK1 phosphorylates BCY1 T129 directly.
Thus, TORC1 activates PKA toward some substrates by preventing MPK1-mediated activation of BCY1.
INTRODUCTION
Cells regulate their growth in response to nutrients. To achieve
this growth control, cells sense and transduce nutrient signals
to coordinate several processes including transcription, ribo-
some biogenesis, translation, nutrient transport and metabo-
lism, and cell morphogenesis and autophagy. In Saccharomyces
cerevisiae, the TOR (Target of Rapamycin) and cAMP-depen-
dent protein kinase A (PKA) signaling pathways are the two
major pathways that transduce nutrient signals to regulate
cell growth (De Virgilio and Loewith, 2006; Santangelo,
2006; Soulard et al., 2009).
TOR is found in two highly conserved and functionally
distinct complexes corresponding to two effector signaling
branches (Wullschleger et al., 2006). Rapamycin-sensitive
TOR Complex 1 (TORC1) mediates temporal control of cell
growth in response to nutrients by promoting anabolic pro-
cesses such as translation and ribosomal protein (RP) gene
expression and by antagonizing catabolic processes such as
autophagy, ubiquitin-dependent protein degradation, and
mRNA degradation (Crespo and Hall, 2002; Loewith et al.,
2002; Reinke et al., 2004; De Virgilio and Loewith, 2006). In
addition, TORC1 regulates lifespan (Kaeberlein et al., 2005).
Rapamycin-insensitive TOR Complex 2 (TORC2) mediates
spatial control of cell growth by regulating actin cytoskele-
ton dynamics, ceramide metabolism, and cell wall integrity
(De Virgilio and Loewith, 2006; Aronova et al., 2008; Cybulski
and Hall, 2009).
PKA in yeast is part of the RAS-cAMP signaling cascade
that controls various growth-related processes in response
to glucose (Santangelo, 2006). Like TORC1, the PKA path-
way regulates translation, ribosome biogenesis, autophagy,
stress responses, glucose metabolism, and lifespan (Santan-
gelo, 2006). The PKA catalytic subunit is encoded by the
three homologous and partly redundant genes TPK1, TPK2,
and TPK3. The PKA regulatory subunit that controls PKA in
response to cAMP is encoded by BCY1 (Cannon and Tatch-
ell, 1987; Toda et al., 1987a,b). In the absence of glucose (i.e.,
a fermentable carbon source), two BCY1s bind two TPKs to
form a catalytically inactive heterotetrameric complex. In the
presence of glucose, adenylate cyclase is activated and pro-
duces cAMP from ATP. cAMP in turn activates PKA by
binding BCY1 and releasing it from TPK (Johnson et al.,
1987; Santangelo, 2006). Furthermore, both TPK1 and BCY1
shuttle between the cytoplasm and the nucleus in growing
cells, with BCY1 mainly in the nucleus and TPK1 primarily
in the cytoplasm (Grifﬁoen et al., 2000, 2001; Schmelzle et al.,
2004).
TORC1 and PKA regulate common target proteins to ac-
tivate or inhibit the same biological processes. For example,
both TORC1 and PKA regulate the nuclear localization of
SFP1 and CRF1, two transcription cofactors involved in RP
gene expression (Jorgensen et al., 2004; Marion et al., 2004;
Martin et al., 2004; Schawalder et al., 2004; Wade et al., 2004).
Similarly, the stress-inducible transcription factors MSN2
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3475and MSN4 are dephosphorylated and rapidly accumulate in
the nucleus upon TORC1 or PKA inhibition (Gorner et al.,
1998; Beck and Hall, 1999). Inhibition of either TORC1 or
PKA also leads to the dephosphorylation, nuclear accumu-
lation, and activation of MAF1, a repressor of RNA poly-
merase III (Moir et al., 2006; Huber et al., 2009; Lee et al.,
2009). Seemingly conﬂicting models have been proposed to
account for the overlapping regulation by TORC1 and PKA.
According to one model, TORC1 and PKA are in distinct but
parallel pathways that converge on common target proteins
or processes. For example, TORC1 and PKA independently
regulate MSN2 and ATG13 phosphorylation (Santhanam et
al., 2004; Stephan et al., 2009). Alternatively, several ﬁndings
suggest that TORC1 is an activator of PKA, placing the two
kinases in the same signaling pathway. First, hyperactiva-
tion of the RAS-cAMP-PKA pathway suppresses a TORC1
deﬁciency, whereas down-regulation of the PKA pathway
leads to increased rapamycin sensitivity (Schmelzle et al.,
2004; Zurita-Martinez and Cardenas, 2005). Second, TORC1
controls RP gene expression via PKA (Martin et al., 2004;
Schmelzle et al., 2004). Third, the AGC kinase SCH9, which
is a direct substrate of TORC1, was initially identiﬁed as a
multicopy suppressor of mutations that reduce PKA activity
(Toda et al., 1988; Urban et al., 2007). Fourth, inactivation of
TORC1 by rapamycin causes a rapid accumulation of the
PKA catalytic subunit TPK1 in the nucleus (Schmelzle et al.,
2004). All together, the above ﬁndings are inconsistent with
a single model to explain the common regulation by TORC1
and PKA.
The cell wall integrity pathway consists of the RHO1-
PKC1-BCK1-MKK1/2-MPK1 signaling cascade. This path-
way allows yeast cells to adapt their growth and shape in
response to cell wall stress (Levin, 2005). Recently, several
reports have linked the cell wall integrity pathway to both
TORC1 and PKA signaling. For example, inactivation of
TORC1 leads to the phosphorylation and activation of the
mitogen-activated protein (MAP) kinase MPK1, and several
components of the cell wall integrity pathway show genetic
interactions with components of the PKA pathway (Verna et
al., 1997; Krause and Gray, 2002; Torres et al., 2002; Park et
al., 2005; Kuranda et al., 2006). However, a molecular link
between TORC1 and PKA via the cell wall integrity pathway
is unknown.
To better understand the relationship between TORC1
and PKA, we further investigated the effect of TORC1 inhi-
bition on PKA. We observed, by large-scale quantitative
phosphoproteome analysis and targeted experiments, that a
distinct subset of PKA target sites become dephosphorylated
upon rapamycin treatment. To investigate the mechanism
by which TORC1 controls PKA, we focused on the PKA
regulatory subunit BCY1. TORC1 regulates PKA by inhibit-
ing phosphorylation of many sites in BCY1 between a
dimerization domain and the cAMP-binding domain.
TORC1 inhibits BCY1 phosphorylation via SCH9 and the
MAP kinase MPK1. Thus, we deﬁne a signaling cascade in
which TORC1 is upstream of PKA toward at least some
substrates.
MATERIALS AND METHODS
Strains, Plasmids, Media, and Genetic Manipulations
The S. cerevisiae strains and plasmids used in this study are listed in Supple-
mentary Tables 1 and 2, respectively. All strains from our laboratory are
isogenic with TB50. Yeast manipulations, including cell cultures, sporulation,
tetrad dissections, and genetic techniques, were carried out essentially as
described by Guthrie and Fink (1991). The media were YPD (1% yeast extract,
1% peptone, 2% dextrose, plus 2% agar for solid media) and minimal syn-
thetic medium (SD; yeast nitrogen base at 6.7 g/l, 2% dextrose, relevant amino
acids and 2% agar for plates). YP medium was used for the glucose depletion
experiment. SDS in YPD was 0.01%. Cells were treated with rapamycin at 200
ng/ml ﬁnal concentration (added from a 1 mg/ml stock solution in 90%
ethanol–10% Tween20) and/or 8-Bromo-cAMP at 5 mM ﬁnal concentration
(from 250 mM stock solution in water). Before 8-Bromo-cAMP treatment, cells
were centrifuged and resuspended in 5 ml of the required medium. In most
experiments, yeast strains carrying a plasmid were precultured in SD medium
lacking the corresponding amino acids for plasmid maintenance and subse-
quently diluted into YPD medium. Cells were then grown for 4–5 h (to OD600
about 0.8) before treatment. For SILAC labeling, yeast cells were grown in SD
medium containing 13C6-arginine and 13C6,15N2-l-lysine (Cambridge Isotope
Laboratories, Andover, MA). Transformations of S. cerevisiae cells were ac-
cording to the lithium acetate method with single-strand carrier DNA and
dimethyl sulfoxide (DMSO; Hill et al., 1991). All deletion and genomically
tagged strains were constructed by PCR-based gene targeting (Wach et al.,
1994). One-step site directed mutagenesis was performed as described previ-
ously (Zheng et al., 2004).
Fluorescence Microscopy
Fluorescence microscopy and indirect immunoﬂuorescence on whole ﬁxed
cells was performed as described previously (Schmelzle et al., 2004).
Protein Extraction, Immunoprecipitation, Western
Blotting, and Phosphatase Treatment
Protein extracts were prepared from exponentially growing cells. At least 25
OD cells were broken in a bead beater in lysis buffer (PBS containing 0.5%
Tween 20 and 10% glycerol) containing 1 Roche protease inhibitor cocktail,
1 mM PMSF, and phosphatase inhibitors (10 mM NaF, 10 mM NaN3,1 0m M
p-nitrophenyl phosphate, 10 mM sodium pyrophosphate, and 10 mM -glyc-
erophosphate). hemagglutinin (HA)-, MYC-, or tandem afﬁnity puriﬁcation
(TAP)-tagged proteins were immunoprecipitated from cell extracts with pro-
tein A-Sepharose beads coupled to anti-HA antibody (12C2A), protein G-
Sepharose beads coupled to anti-MYC antibody (1-9E10.2), or human IgG-
Sepharose beads (GE Healthcare, Waukesha, WI), respectively. For the
phosphatase experiment, beads were further washed with phosphatase buffer
(50 mM Tris-Cl, pH 7.5, 1 mM MgCl2), resuspended in 100 l phosphatase
buffer, and incubated for 10 min at 30°C. Twenty units of calf intestine
alkaline phosphatase was added, and the reaction was incubated for 15 min
30°C. For the gel-shift assay, the acrylamide-bisacrylamide ratio for SDS-
PAGE was changed to 172:1. The primary antibodies for Western blotting
were as follows: anti-HA (mouse monoclonal, 12C2A), anti-MYC (mouse
monoclonal, 1-9E10.2), anti-protein A (rabbit polyclonal, Sigma-Aldrich, St.
Louis, MO), anti-BCY1 (goat polyclonal, Bcy1 [yN19] sc-6765, Santa Cruz
Biotechnology, Santa Cruz, CA), anti-RxxS/T (rabbit polyclonal phospho-
[Ser/Thr] PKA substrate antibody no. 9621, Cell Signaling, Beverly, MA),
anti-RRxS/T (phospho-PKA Substrate [RRXS/T; 100G7E], rabbit mAb no.
9624, Cell Signaling), anti-MPK1 (goat polyclonal, Mpk1 [yC-20] sc-6803,
Santa Cruz Biotechnology), anti-phospho MPK1 (rabbit polyclonal, phospho-
p44/42 MAPK [Thr202/Tyr204] antibody no. 9101, Cell Signaling). (The
phosphorylated residues are underlined.)
Identiﬁcation of Phosphorylation Sites in BCY1
Wild-type TB50a cells or cells expressing N-terminally H- tagged BCY1
(SA094) were grown in 500 ml YPD to OD600 nm of 1 and treated with
rapamycin (200 ng/ml) or drug vehicle for 90 min. Cells were broken with
glass beads with RIPA buffer (25 mM Tris-Cl, pH 7.5, 150 mM NaCl, 1%
Nonidet NP-40, 1% Na-deoxycholate) supplemented with 1 Roche protease
inhibitor cocktail and phosphatase inhibitors (10 mM NaF, 0.2 M okadaic
acid, and 20 nM calyculin A). HA-tagged BCY1 was immunoprecipitated
from 40 mg of total protein extract with 1 l of monoclonal anti-HA antibody
(HA.11; Covance, Princeton, NJ) at 4°C for 18 h followed by incubation with
100 l of Dynabeads protein G (Invitrogen, Carlsbad, CA) for4ha t4°C. The
beads were washed and HA-BCY1 was eluted from the beads with 10 l3M
urea, and 20 mM DTT for 10 min at room temperature. HA-BCY1 was digested
with trypsin for 18 h at 37°C. Proteolysis was stopped with 8.4 l acetic acid, and
the peptides were dried in a Speed Vac. Phosphopeptides were enriched with
TiO2-magnetic beads (Perkin Elmer-Cetus, Waltham, MA) according to the man-
ufacturer’s instructions. The ﬁnal peptides were analyzed by capillary liquid
chromatography tandem MS (LC/MS/MS) using a 300SB C-18 column (0.3 
50 mm; Agilent Technologies, Basel, Switzerland) connected on line to an
LTQ-Orbitrap hybrid instrument (Thermo Finnigan, San Jose, CA; see below).
Glycogen Staining
Staining of intracellular glycogen was performed with iodine vapor as pre-
viously described (Barbet et al., 1996).
MPK1 Kinase Assay
Yeast cells expressing HA-tagged MPK1 were grown in 500 ml YPD to an
OD
600 nm of 1 and then treated for 30 min with rapamycin or drug vehicle.
Protein extraction, immunoprecipitation, and in vitro kinase assays were
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Modiﬁed RIPA buffer (25 mM Tris-Cl, pH 7.5, 150 mM NaCl, 1% Nonidet
NP-40, 1% Na-deoxycholate) was used to break the cells, and 20 mg of total
protein extract was used for the immunoprecipitation. The TB50a wild-type
strain was used as mock control. A fraction of total lysate (20 g) was kept to
check MPK1-HA expression and phosphorylation on Western blots.
Zymolyase Sensitivity Assay
Zymolyase sensitivity was tested as reported (Ho et al., 2005).
Phosphoproteome Analysis: SILAC Labeling and Protein
Extraction
Two 200-ml cultures of YPJ2 cells (derived from TB50a) were grown at 30°C
in SD medium supplemented with either 30 mg/l 12C6-arginine and 12C6-
lysine (“light” culture) or 13C6 l-arginine and 13C6,15N2 l-lysine (“heavy”
culture) to an optical density (600 nm) of 0.7. The heavy culture was treated
for 15 min with 200 nM rapamycin, whereas the light culture was treated
mock-treated with the vehicle for 15 min. To produce reliable quantitative
data, four biological replicates were performed, always starting from a single
yeast clone. In one of the four experiments the labeling was swapped to check
that the labeling inﬂuences neither protein expression nor phosphorylation.
After rapamycin treatment, both cell cultures were centrifuged at 3500  g for
10 min at 4°C, and the cell pellets were washed with ice-cold water.
The cell pellets were individually resuspended in 2 ml ice-cold lysis buffer,
containing 100 mM Tris-HCl, pH 7.5, 2.5% SDS, 10% glycerol, 1 protease
inhibitor cocktail (Roche Diagnostics, Indianapolis, IN; dissolved in ddH2O),
1 phosphatase inhibitor cocktail 1 (Sigma-Aldrich, dissolved in 100%
DMSO) and 1 mM PMSF (AppliChem, Darmstadt, Germany; dissolved in
100% DMSO). Total protein extraction from either light or heavy cultures was
performed by bead-beating as described above. The lysates were cleared at
15,000  g for 10 min at 4°C. Protein concentrations in the extracts were
measured with the bicinchonic acid assay (BCA, Sigma-Aldrich). About 2.5
mg of light- or heavy-labeled protein extracts were mixed and after addition
of 6 sample buffer were incubated at 95°C for 5 min and subjected to
preparative electrophoresis.
Phosphoproteome Analysis: Protein Fractionation and
In-Gel Digestion
The mixed protein extracts were separated on a preparative 10% SDS slab gel.
After electrophoresis, the gel was stained with SimplyBlue SafeStain (Invitro-
gen). The gel was then sliced horizontally into 16 regions, and the individual
slices were further diced into 1-mm3 cubes. The gel pieces were destained
overnight in 1 ml 50% acetonitrile/50 mM NH4HCO3, dehydrated with 500 l
100% acetonitrile, and dried in a speed-vac. The proteins were in-gel reduced
i n1m l5 0m MN H 4HCO3 containing 10 mM DTT at 55°C for 60 min.
Alkylation was done in 1 ml 50 mM iodoacetamide (in 50 mM NH4HCO3)i n
the dark for 30 min. After the gel pieces were washed three times with 1 ml
50% acetonitrile/50 mM NH4HCO3, they were dehydrated with 500 l 100%
acetonitrile, dried in a speed-vac, and then rehydrated on ice for1hi n1m l
50 mM NH4HCO3, pH 8.0, containing 15 ng/l trypsin (Sigma). Digestion
was carried out overnight at 37°C. Supernatants were collected in fresh tubes
and the gel pieces were extracted three times with 50% acetonitrile/5% formic
acid, followed by a ﬁnal extraction with 100% acetonitrile. The volume of the
individual digests was reduced in a speed-vac to 10 l to which 290 l1 %
acetic acid was added. A small drop was spotted onto pH paper, and if
necessary the pH was adjusted to 2.0–2.5 with 10% acetic acid.
Phosphoproteome Analysis: Peptide Desalting and
Phosphopeptide Enrichment
For phosphopeptide enrichment, the digests were desalted on C18 MacroSpin
columns (500 l packed resin, The Nest Group, Southborough, MA) accord-
ing to the manufacturer’s instructions. The peptides were eluted from the
cartridge with 600 l 60% acetonitrile/1% acetic acid. The eluates were
speed-vac dried to 10 l to which 90 l IMAC-buffer (30% acetonitrile/250
mM acetic acid) was added. One microliter of each digest was diluted 200-fold
with 2% acetonitrile/0.1% acetic acid, and 10 l was analyzed by LC/MS/MS
for expression analysis.
For phosphopeptide enrichment, 40 l IMAC slurry (PHOS-Select, Sigma-
Aldrich) was washed ﬁve times with 1 ml IMAC-buffer and then loaded into
a constricted GELoader tip (Thingholm et al., 2006). The desalted digests were
applied to the IMAC columns. The ﬂow-throughs were collected and re-
loaded ﬁve times to ensure maximal binding. The resin was washed three
times with 150 L IMAC-buffer. Bound phosphopeptides were eluted with
three successive 70-l desorptions of 50 mM KH2PO4, pH 10.0, into Eppen-
dorf tubes containing 30 l 10% formic acid. The IMAC eluates were desalted
on disposable C18 MicroSpin columns (MA100 l packed volume, The Nest
Group) according to the manufacturer’s instructions. After elution with 200 l
60% acetonitrile/1% acetic acid, the volume was reduced in a speed-vac to
10 l, and the phosphopeptides were diluted with 40 l 2% acetonitrile/
0.1% formic acid for LC-MS/MS analysis.
Phosphoproteome Analysis: LC-MS/MS Analysis
LC-MS/MS analysis was performed on an LTQ-Orbitrap hybrid instrument
(Thermo Scientiﬁc). Ten microliters of IMAC eluate was injected with an
autosampler (CTC Analytics, Agilent Technologies, Basel, Switzerland) onto a
C18 trapping column (300SB C-18 0.3  50 mm, Agilent Technologies) that
was connected to a separation column (0.1 mm  10 cm) packed with Magic
300 Å C18 reverse-phase material (5-m particle size, Michrom Bioresources,
Auburn, CA). A linear 80-min gradient from 2 to 50% solvent B (80% aceto-
nitrile/0.1% acetic acid) in solvent A (2% acetonitrile/0.1% acetic acid) was
delivered with a Rheos 2200 pump (Flux Instruments, Basel, Switzerland) at
a ﬂow rate of 100 l/min. A precolumn split was used to reduce the ﬂow to
300 nl/min. The eluting peptides were ionized at 1.7 kV.
The LTQ-Orbitrap was operated in data-dependent mode. A survey scan
between m/z 375 and 1600 was acquired in proﬁle mode in the Orbitrap at
60,000 resolution, and the 10 most abundant ions were then selected for
fragmentation in the LTQ part of the instrument at normalized collision
energy of 35%. To facilitate fragmentation of phosphopeptides, a CID scan
was followed by multistage activation. Singly charged ions were omitted
from fragmentation, and previously selected ions were dynamically excluded
for 25 s. Scan-to-scan calibration was allowed by setting the lock mass to m/z
445.120025 (Olsen et al., 2005).
Phosphoproteome Analysis: Database Search, Statistics,
and Quantitation
To obtain statistically relevant quantitative phosphoproteomes, four indepen-
dent SILAC experiments from either untreated or rapamycin-treated cell
cultures were collected. The MS data were processed with MaxQuant (version
1.0.12.31;Max Plank Institute of Biochemistry, Martinsreid, Germany) and
searched with the Mascot search engine (version 2.2.04, Matrix Science, Lon-
don, United Kingdom) against a databank containing 31,426 protein se-
quences (Perkins et al., 1999; Cox and Mann, 2008; Cox et al., 2009). The
databank contained forward and reverse S. cerevisiae sequences as well as
common contaminants (Swiss-Prot; from European Bioinformatics Institute;
http://www.ebi.ac.uk/uniprot). Precursor ion and fragment ion mass toler-
ances were set to 7 ppm and 0.6 Da, respectively. Two missed cleavages were
allowed. Dynamic modiﬁcations were oxidation for methionine and phos-
phorylation of serine, threonine, and tyrosine, whereas cysteine carbamidom-
ethylation was set as ﬁxed modiﬁcation. To increase identiﬁcation stringency
only peptides with a Mascot score above 20 were accepted. In addition, only
MS/MS spectra with a posterior error probability (PEP) below 0.1 were
accepted (Hilger et al., 2009). The MaxQuant output was simpliﬁed by replac-
ing oxidized with unmodiﬁed methionines. In addition, proteins matching
the same (phospho)peptides were merged into one hit. Gene products of the
Ty retrotransposons and the S. cerevisiae virus L-A were manually removed.
For expression analysis, all peptides belonging to the same protein were
merged, whereas for phosphorylation analysis, all redundant phosphopep-
tides containing the same phosphorylation site(s) were grouped together. To
evaluate the biological reproducibility of the four experiments, the ratios of
the heavy labels to light labels obtained in one experiment were compared
with all other experiments. A high correlation was obtained for all four
experiments, indicating good reproducibility throughout the entire study
(Supplementary Figure 1A). To ﬁnd changes in expression or phosphoryla-
tion that are above the experimental error, an experiment was done without
rapamycin treatment. The SILAC ratios were log2 transformed, and the ex-
perimental average and SDs were found to be 0.02 and 0.28 (SDcontrol),
respectively. Then, the SILAC ratios of the four cell cultures were log2
transformed, and for those proteins or phosphopeptides that occurred in
more than one experiment, a 95% conﬁdence interval was calculated along
with the median of the log ratios to assess the inﬂuence of outliers. Up-
regulation of expression or phosphorylation was considered signiﬁcant when
the lower conﬁdence limits were more than or equal to 0.56 (twice the
SDcontrol). Likewise, down-regulation of protein expression or the extent of
phosphorylation was considered signiﬁcant when the upper conﬁdence limit
was less than or equal to 0.56. Those proteins or phosphopeptides that were
found in only one experiment but also that showed a large change in abun-
dance or phosphorylation were accepted only if the log2-transformed ratios
were more than 1.12 or less than 1.12 (four times SDcontrol). The choice of
these two thresholds (two and four times the SD of the control, respectively)
was made in a conservative way, in order to minimize the number of false
positive we obtained. Notably, by using these two selection criteria, among
the regulated hits we found many proteins that were already known to be
controlled by TORC1 (Supplementary Figure 1, C and D).
RESULTS
PKA Sites Are Primary Targets for TORC1-dependent
Phosphorylation
Although it is known that TORC1 regulates many cellular
processes, the molecular mechanisms by which TORC1 sig-
nals to these diverse processes are often not well under-
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its direct effectors such as the AGC kinase SCH9 are known.
To identify proteins whose phosphorylation changes in a
TORC1-dependent manner, we performed unbiased quanti-
tative phosphoproteomic analysis by stable isotope labeling
with amino acids in cell culture (SILAC; Ong et al., 2002).
Extracts from rapamycin-treated untreated yeast cells were
separated by preparative SDS gel electrophoresis, phos-
phopeptides were enriched by IMAC, and the resulting
phosphopeptide pools were analyzed by LC-MS/MS (Fig-
ure 1A). Unique phosphopeptides (n  2487) and unique
phosphorylation sites (n  2607), corresponding to 972
phosphoproteins, were identiﬁed and quantiﬁed (Figure 1B
and Supplementary Table 3). Our phosphoproteome com-
pares favorably to previously published yeast phosphopro-
teomes (Gruhler et al., 2005; Li et al., 2007; Wilson-Grady et
al., 2008) and includes both high- and low-abundance phos-
phoproteins (Supplementary Figure 1B; Ghaemmaghami et
al., 2003). Of the 972 phosphoproteins identiﬁed (Supple-
mentary Table 3), 78 were signiﬁcantly hyperphosphory-
lated, and 55 were hypophosphorylated upon rapamycin
treatment (Supplementary Tables 4 and 5, respectively). To
accurately quantify the changes in phosphorylation, the fold
change in phosphorylation was systematically compared
with the fold change in expression for each protein (Supple-
mentary Tables 6–8). Analysis of the data revealed that
many rapamycin-regulated phosphoproteins had been already
genetically or biochemically linked to TORC1 signaling (Sup-
plementary Figure 1, C and D), providing further validation of
our phosphoproteome. During the preparation of this manu-
script, another study describing the rapamycin-regulated phos-
phoproteome in yeast was published (Huber et al., 2009). A
comparison of the two studies revealed surprisingly little over-
lap. Although the total number of rapamycin-regulated pro-
teins was very similar in the two studies (133 vs. 129), only 29
proteins were common to both studies (Supplementary Figure
1, C and D). Thus, the two studies provide different but com-
plementary rapamycin-regulated phosphoproteomes.
To determine if TORC1 controls phosphorylation of
speciﬁc motifs, we analyzed the sequences surrounding
the rapamycin-regulated phosphosites, with the Motif-X
algorithm (Schwartz and Gygi, 2005). For the peptides
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Figure 1. Quantitative analysis of the rapa-
mycin-sensitive phosphoproteome by SILAC.
(A) Schematic overview of the experimental
approach for the identiﬁcation of TORC1 reg-
ulated phosphorylation sites in S. cerevisiae.
Two yeast cultures (strain YPJ2) were metabol-
ically labeled with 12C6-14N2-lysine/12C6-argi-
nine (light) or 13C6-15N2-lysine/13C6-arginine
(heavy). The heavy culture was treated for 15
min with rapamycin. Extracts were mixed in a
1:1 ratio and separated by preparative SDS-
PAGE. The gel was horizontally sliced into 16
sections and in-gel–digested, and phosphopep-
tides were IMAC-enriched and analyzed in an
LTQ-Orbitrap. (B) Merged data from the four
experiments revealed 972 phosphoproteins,
corresponding to 2487 unique phosphopeptides
and 2607 unique phosphosites. (C) Analysis by
Motif-X of all regulated phosphopeptides.
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Molecular Biology of the Cell 3478whose phosphorylation was down-regulated upon rapa-
mycin treatment, the top scoring target motif was RRxS
(the phosphorylated residue is underlined; Figure 1C). This
motif was underrepresented in the phosphopeptides whose
phosphorylation was up-regulated (Figure 1C). The related
motif RxxS appeared in both the up- and down-regulated
phosphopeptides (Figures 1C). Finally, the two motifs SP and
SxxS were also represented, but only in the up-regulated
peptides. Examination of the rapamycin-sensitive phospho-
proteome presented by Huber et al. (2009) revealed a similar
bias toward RRxS sites for down-regulated phosphopeptides
(Supplementary Table 9). Thus, RRxS is a primary target motif
for TORC1-dependent phosphorylation.
Importantly, RRxS/T is the consensus target motif specif-
ically recognized and phosphorylated by PKA (Shabb, 2001;
Budovskaya et al., 2005). Of the 55 proteins whose phosphor-
ylation was decreased upon rapamycin-treatment, 10 were
hypophosphorylated at this PKA target motif. The 10 pro-
teins were FRA1, GCN2, KCS1, KSP1, LHP1, MAF1, MKS1,
SSD1, VTC2, and YJL016W (Table 1). FRA1, KSP1, LHP1,
MAF1, and SSD1 have been shown to be PKA targets in vitro
(Budovskaya et al., 2005; Ptacek et al., 2005). MAF1 is phos-
phorylated and negatively regulated by PKA and TORC1 in
vivo (Moir et al., 2006; Huber et al., 2009; Lee et al., 2009; Wei
et al., 2009). The localization of the protein kinase KSP1 is
inﬂuenced by PKA (Bharucha et al., 2008), and GCN2, KCS1,
KSP1, LHP1, MKS1, and SSD1 have been linked to TORC1
and/or PKA signaling either genetically or biochemically
(SGDproject;SaccharomycesGenomeDatabase;http://www.
yeastgenome.org/; Xie et al., 2005; Huber et al., 2009). Thus,
TORC1 appears to mediate phosphorylation of PKA target
sites.
It is also important to note that many phosphorylated
PKA target motifs in our phosphoproteome were not af-
fected by rapamycin treatment (Supplementary Table 3).
These included the PKA sites in the three well-known PKA
targets MSN2, BCY1, and NTH1 (Supplementary Table 3).
Thus, TORC1 appears to mediate phosphorylation of only a
subset of PKA target sites.
TORC1 Activates PKA toward Certain Substrates
The above ﬁndings suggested that TORC1 activates PKA at
least toward a subset of substrates. To investigate whether
TORC1 indeed activates PKA, we performed targeted anal-
yses of individual PKA substrates. In particular, we inves-
tigated the effect of rapamycin treatment on the in vivo
steady-state phosphorylation of the known or suspected
PKA substrates MAF1, YPK3, and KSP1. We probed the
phosphorylation of these PKA substrates with an antibody
that speciﬁcally recognizes a phosphorylated consensus
PKA target motif (RRxS/T). This antibody is hereafter re-
ferred to anti-RRxS/T.
Consistent with our phosphoproteome analysis and as
reported previously, we observed that MAF1 phosphoryla-
tion at PKA consensus sites was strongly reduced upon
rapamycin treatment (Figure 2A). Although this could sug-
gest that TORC1 activates PKA toward MAF1, this interpre-
tation is complicated by the fact that the TORC1 effector
SCH9, an AGC kinase family member like PKA, can also
directly phosphorylate PKA sites in MAF1 (Huber et al.,
2009; Lee et al., 2009). To further investigate whether TORC1
indeed activates PKA toward MAF1, we used the cell-per-
meable phosphodiesterase resistant analogue 8-Bromo-
cAMP (Verma et al., 1988) to activate PKA in the absence of
TORC1 and SCH9 activity. As expected, PKA inactivation
upon glucose starvation resulted in a strong reduction in
MAF1 phosphorylation at PKA sites, and addition of 8-Br-
cAMP to glucose-starved cells restored MAF1 phosphoryla-
tion at PKA sites (Figure 2B and Supplementary Figure 2A).
Treatment of cells with 8-Br-cAMP also counteracted the
inhibitory effect of rapamycin on the phosphorylation of
MAF1 at PKA sites (Figure 2C and Supplementary Figure
2B). These data suggest that TORC1 indeed activates PKA
(in addition to SCH9) toward MAF1.
We also examined phosphorylation of PKA sites in YPK3
and KSP1. YPK3 is an AGC kinase that is phosphorylated by
PKA in vitro (Budovskaya et al., 2005; Ptacek et al., 2005).
KSP1 is a serine/threonine kinase required during ﬁlamen-
tous growth in response to nutrient limitation (Bharucha et
al., 2008). KSP1 localization is inﬂuenced by PKA, and it is
also a PKA substrate in vitro (Ptacek et al., 2005; Bharucha et
al., 2008). Similar to MAF1 and again consistent with our
phosphoproteome analysis, phosphorylation of both KSP1
and YPK3 at consensus PKA site(s) decreased upon rapa-
mycin treatment (Figure 2A). Similar to MAF1, but to a
lesser extent, activation of PKA with 8-Br-cAMP counter-
Table 1. Proteins for which phosphorylation decreased at PKA consensus motif RRxS after rapamycin treatment
Protein Phospho sitea Descriptionb (SGD)
FRA1 S 56 (0.48  0.16) Protein involved in negative regulation of transcription of iron regulon
GCN2 S 577 (0.18  0.02) eIF2 kinase regulating translation in response to starvation
KCS1 S 537 (0.42) Inositol hexakisphosphate (IP6) and inositol heptakisphosphate (IP7) kinase
KSP1 S 827 (0.27  0.01) Ser/thr protein kinase required for haploid ﬁlamentous growth
S 883, S 884 (0.11)
S 884 (0.40)
LHP1 S 19 (0.51  0.13) RNA-binding protein required for maturation of tRNA and U6 snRNA precursors
MAF1 S 90 (0.25  0.08) Negative regulator of RNA polymerase III in response to nutrients and stress
S 209 (0.29)
MKS1 S 518 (0.43  0.18) Negative transcriptional regulator involved in Ras-cAMP and lysine biosynthetic
pathways, and nitrogen regulation
SSD1 S 164 (0.56  0.07) Maintenance of cellular integrity, interacts with components of the TOR pathway
VTC2 S 583 (0.24  0.03) Subunit of the vacuolar transporter chaperone (VTC) complex involved in
membrane trafﬁcking
YJL016W S 350 (0.50  0.02) Putative protein of unknown function
a For each protein the coordinate of the regulated phospho-site and the fold-increase the average ratio (SD) are given in parentheses. No
SD indicates that the phospho-sites were identiﬁed in only one experiment.
b The description of the function of the protein is given according to the SGD with adaptation.
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lation of YPK3 at PKA sites (Figure 2D). We did not examine
the effect of 8-Br-cAMP on KSP1 for technical reasons. The
above taken together indicates that MAF1, YPK3, and likely
KSP1 are phosphorylated by PKA in a TORC1-dependent
manner.
Type 2A and type 2A-like phosphatases are well-known
downstream effectors of TORC1 and are activated upon
TORC1 inactivation (Jiang and Broach, 1999; Jacinto et al.,
2001; Crespo and Hall, 2002). We have reported previously
that the effect of TORC1 inhibition on several PKA-depen-
dent processes is independent of both PP2A and the PP2A-
like phosphatase SIT4 (Martin et al., 2004; Schmelzle et al.,
2004). The above results with 8-Br-cAMP also suggest that
the rapamycin-induced decrease in PKA target site phos-
phorylation is due to loss of PKA activity rather than to
activation of a phosphatase.
We also used anti-RRxS/T to probe MSN2, CDC25, YAK1,
and CKI1, all PKA substrates but whose PKA site phosphor-
ylation was either not detected (CDC25, YAK1, and CKI1) or
not altered in response to rapamycin (MSN2) in our phos-
phoproteome analysis. Probing with anti-RRxS/T detected
all four proteins but failed to detect a change in their phos-
phorylation upon rapamycin treatment (see Supplementary
Figure 3). Thus, large scale and targeted analyses of PKA site
phosphorylation suggest that TORC1, rather than activating
PKA globally, selectively activates PKA toward a subset of
substrates.
BCY1 Is Highly Phosphorylated upon TORC1 Inactivation
To obtain insight into the molecular mechanism by which
TORC1 might regulate PKA, we focused on BCY1. After
conﬁrming earlier observations that physiologically relevant
TPK1–BCY1 interaction cannot be monitored in vitro or in
vivo (Supplementary Figure 4 and data not shown), we
examined BCY1 phosphorylation. As shown previously,
BCY1 is highly phosphorylated upon glucose starvation,
and this phosphorylation appears to be important for PKA
nuclear localization, suggesting that BCY1 phosphorylation
leads to BCY1 activation and PKA inactivation (Werner-
Washburne et al., 1991; Grifﬁoen et al., 2001). We observed
that rapamycin treatment resulted in a slower migrating,
phosphatase-sensitive form of BCY1 (Figure 3A), suggesting
that TORC1 might signal to PKA via inhibition of BCY1
phosphorylation.
To investigate further whether TORC1 signals to PKA via
BCY1 phosphorylation, we identiﬁed the phosphorylation
sites in HA-tagged BCY1 isolated from rapamycin-treated
and untreated cells (see Materials and Methods). In total, 17
phosphorylation sites were identiﬁed (Figure 3B and Sup-
plementary Table 10). The 17 sites fell into three clusters, all
in the N-terminal part of BCY1 (Figure 3B). The ﬁrst cluster
was S68, S70, S74, S77, S79, S81, S83, and S84. This cluster of
phosphorylation sites, termed cluster II (CII), was described
previously and was shown to be important for BCY1 func-
tion (Grifﬁoen et al., 2001). The second cluster of phosphor-
ylated residues consisted of T144, S145, S147, T150, and
T160. This cluster falls within or near the so-called autoin-
hibitory domain where the catalytic subunit of PKA “auto-
phosphorylates” the highly conserved S145 (RRxS145)t oi n -
hibit BCY1 (Kuret et al., 1988; Werner-Washburne et al.,
1991). The third cluster of phosphorylated residues included
T129, S130, and T131. This cluster was novel and was termed
cluster III (CIII). We note that, in addition to the above 17
phosphorylation sites, we also detected phosphorylation in
an extreme N-terminal, HA-containing fragment of BCY1,
but were unable to pinpoint the phosphorylated residue(s)
(data not shown). This phosphorylation is presumably re-
lated to the previously identiﬁed cluster I (CI; Grifﬁoen et al.,
2001).
Consistent with the above observation that rapamycin
treatment induced BCY1 phosphorylation as measured by
altered electrophoretic mobility (Figure 3A), we detected
more BCY1 phosphopeptides in extracts from rapamycin-
treated cells compared with untreated cells. In particular,
sites in CIII (and to a lesser extend in CII) were hyperphos-
phorylated in response to rapamycin (Supplementary Table
10). These results suggest that there are many TORC1-sen-
sitive phosphorylation sites in BCY1, mainly in CIII. This
may explain why previous studies, which did not examine
rapamycin-treated cells, did not detect the phosphorylation
sites in CIII.
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Figure 2. Inﬂuence of TORC1 inhibition on PKA substrate phosphor-
ylation in vivo. (A) Rapamycin affects the phosphorylation state of
different PKA substrates. Yeast strains expressing MAF1-HA (SA148),
YPK3-HA (SA216), or KSP1-HA (SA219) were grown to exponential
phase and treated for the indicated time with 200 ng/ml rapamycin
() or drug vehicle (). After protein extraction each tagged protein
was immunoprecipitated and analyzed by Western blot for total
protein (tot) with anti-HA antibody and for phosphorylation at PKA
site (PKA) with anti-RRxS/T antibody. TB50a was used for mock
control. (B) The yeast strain SA148 expressing MAF1-HA was
grown to exponential phase in YPD and then shifted or not to YP for
2 h. Aliquots of cells were then treated for 30 min with 5 mM of
8-Br-cAMP. MAF1-HA was immunoprecipitated from total cell ly-
sate and analyzed as described in A. TB50a was used as mock
control. For each condition, the phosphorylation at PKA sites was
quantiﬁed and normalized against the level of total protein and
expressed as a percentage [Phos/tot (%)]. (C) The yeast strain SA148
expressing MAF1-HA was grown to exponential phase in YPD and
then pretreated or not with 5 mM of 8-Br-cAMP during 5 min.
Aliquots of cells were then treated for 30 min with 200 ng/ml rapa-
mycin. Phosphorylation of MAF1-HA was analyzed as in A and B.
TB50a was used for mock control. Phosphorylation was quantiﬁed as
in B [Phos/tot (%)]. (D) The yeast strain SA216 expressing YPK3-HA
was treated and analyzed as in C.
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Molecular Biology of the Cell 3480S145 is part of an RRxS motif, whereas S74, S83, and T129
are part of RxxS/T sequences. To further characterize the
rapamycin-induced phosphorylation sites in BCY1, we took
advantage of two antibodies, the previously described anti-
RRxS/T that speciﬁcally recognizes a phosphorylated PKA
site (e.g., phosphorylated S145) and a second antibody (anti-
RxxS/T) that recognizes the related, phosphorylated motif
RxxS/T (e.g., phosphorylated T129). As described below
and in supplementary information, the speciﬁcity of the two
antibodies was conﬁrmed by mutagenesis of their recogni-
tion sites in BCY1 (Figure 4A and Supplementary Figure 7).
As shown in Figure 3C, HA-BCY1 immunoprecipitated with
anti-HA was detected with both anti-RRxS/T and anti-
RxxS/T. Although the signal obtained with anti-RRxS/T did
not change signiﬁcantly upon rapamycin treatment [Figure
3C, see P-BCY1 (S145)], the signal observed with anti-
RxxS/T increased upon TORC1 inhibition [Figure 3C, see
P-BCY1(T129)]. Thus, consistent with BCY1 phosphosite-
mapping experiments described above, TORC1 inhibits
phosphorylation of RxxS/T sites in BCY1 and has no effect
on RRxS145 phosphorylation.
To conﬁrm that the effect of rapamycin on BCY1 phos-
phorylation was indeed due to inhibition of TORC1, we
examined BCY1 phosphorylation in TOR mutant strains. In
a TOR1 deletion strain, BCY1 was hyperphosphorylated at
the RxxS/T site(s). Conversely, this site(s) remained insen-
sitive to rapamycin in the rapamycin resistant (TORRR)
TOR1-1 TOR2-1 strain (Figure 3D). Thus, the effect of rapa-
mycin on phosphorylation of BCY1 at the RxxS/T motif was
due to TORC1 inhibition. Furthermore, phosphorylation of
the RxxS/T motif in BCY1 increased with increasing time of
rapamycin treatment, reaching a level after 2 h comparable
to that of glucose starvation for 2 h (Figure 3E). Taken
together, the above results suggest that TORC1 (and glu-
cose) inhibits phosphorylation of multiple sites in BCY1,
some if not all of which are part of an RxxS/T motif (e.g.,
S74, S83, and T129).
TORC1-sensitive BCY1 T129 Phosphorylation Inactivates
PKA
To determine the effect of TORC1-sensitive BCY1 phosphor-
ylation on PKA function, we mutated individually S74, S83,
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Figure 3. The PKA regulatory subunit BCY1 is highly phosphor-
ylated upon TORC1 inhibition. (A) Exponentially growing cells
expressing HA-BCY1 from a plasmid (SA094) or not (TB50a) were
treated for 2 h with drug vehicle or rapamycin at 200 ng/ml. Total
proteins were extracted and HA-BCY1 was immunoprecipitated.
Aliquots of IPs belonging to the rapamycin treated samples were
further treated with phosphatase (PPase) or not, in presence of
phosphatase inhibitors (PPi) or not. BCY1 phosphorylation was
observed by gel-shift assay followed by Western blotting with an
anti-HA antibody. (B) Graphical representation of the phosphory-
lated amino acids identiﬁed in BCY1 by phosphopeptide enrich-
ment and MS. CII/III, cluster II/III. (C) Similar to A except that
yeast cells were treated with rapamycin for 45 min (Rap). Total
BCY1 was followed by Western blot with anti-BCY1 (BCY1) anti-
body and the different phosphorylated form of BCY1 with anti-
RRxS/T antibody [(BCY1-P (S145)] and anti-RxxS/T antibody
[BCY1-P (T129)], respectively. (D) The procedure used in B was
used to analyze rapamycin-induced phosphorylation of HA-BCY1
in wild-type (WT  TB50a), TOR1 deletion (tor1AN9-2a), and
rapamycin resistant TORs (TORRR  TOR1-1 TOR2-1  RL206-4D)
yeast strain carrying pTS137 (panel IP). In parallel, total (MPK1) and
activated MPK1 (MPK1-P) were visualized by Western blot on the
total cell lysates used for the HA-BCY1 IPs (panel total). (E) Wild-
type cells (WT  SA094) expressing HA-BCY1 (pTS137) were
treated with 200 ng/ml rapamycin (Rap) or shifted to YP medium
lacking glucose (Glu) for the indicated time. Total (HA-BCY1) and
phosphorylated BCY1 [BCY1-P (T129)] were followed as in D.
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Figure 4. BCY1 T129 phosphorylation after rapamycin treatment
lowers PKA activity. (A) The yeast strains expressing wild-type
(WT) or different mutants of HA-BCY1 at threonine 129 (T129A,
T129D) were grown to exponential phase and treated or not with
rapamycin (200 ng/ml) for 45 min. After total protein extraction,
HA-BCY1 was immunoprecipitated. Total BCY1 and phosphory-
lated BCY1 at S145 and T129 were detected by Western blot with
the corresponding antibodies. (B) The yeast strains used in A
were grown to exponential phase. A cell quantity corresponding to
1.0 OD600 nm was serially 10-fold diluted and spotted on YPD plates
containing DMSO or 5 ng/ml rapamycin. Plates were then incu-
bated at 30°C for 3–5 d. (C) Glycogen accumulation was tested by
iodine staining after 5-h rapamycin or drug vehicle treatment of
yeast strains expressing the wild-type (BCY1  SA094) and mutated
form of BCY1 at threonine 129 (T129A and T129D).
TORC1 Regulates PKA through MPK1
Vol. 21, October 1, 2010 3481and T129 to alanine or to phosphomimetic aspartate. Each
mutant was then examined for rapamycin sensitivity and
rapamycin-induced glycogen accumulation, two pheno-
types that reﬂect PKA inactivity (Schmelzle et al., 2004;
Zurita-Martinez and Cardenas, 2005). We note that mutation
of T129 reduced recognition by anti-RxxS/T, whereas mu-
tation of S74 and S83 had no effect on recognition by this
antibody (Figure 4A and data not shown). Thus, the region
containing T129 was the main epitope in BCY1 recognized
by anti-RxxS/T (Figure 4A). The phosphomimetic mutation
BCY1T129D conferred increased sensitivity to rapamycin and
enhanced accumulation of glycogen upon TORC1 inhibition
(Figure 4, B and C), suggesting that the BCY1T129D protein is
a constitutive inhibitor of PKA and that T129 phosphoryla-
tion activates BCY1 to inhibit PKA (at least toward some
substrates). However, BCY1T129A behaved like wild-type
BCY1, as determined by rapamycin sensitivity and glycogen
accumulation. Furthermore, mutation of T129 to alanine or
aspartate did not affect nuclear localization of BCY1, rapa-
mycin-dependent nuclear localization of TPK1, BCY1-TPK1
interaction, or PKA-dependent phosphorylation of MAF1
(data not shown). These results suggest that phosphoryla-
tion of a site(s) other than T129 can also activate BCY1. This
other site is likely not S74, S83, or T131, as mutation of any
one of these sites had no phenotypic consequence in our
assays (data not shown). Taken together, our results suggest
that TORC1 controls PKA (at least toward some substrates)
by inhibiting phosphorylation of T129 and possibly other so
far unknown sites in BCY1.
TORC1 Controls PKA via SCH9
As reported recently, TORC1 directly phosphorylates and
activates the serine/threonine kinase and S6K homolog
SCH9 (Urban et al., 2007). Several reports have suggested
that SCH9 is linked to PKA signaling. For example, the
SCH9 gene was initially identiﬁed as a multicopy suppressor
of mutations that reduce PKA activity, and SCH9 prevents
glycogen accumulation and activates ribosomal protein gene
expression similar to PKA (Toda et al., 1988; Urban et al.,
2007). To determine whether TORC1 controls BCY1 (and
PKA) via SCH9, we examined BCY1 T129 phosphorylation
in SCH9-deleted cells. As shown in Figure 5A, BCY1 was
hyperphosphorylated at T129 in the sch9 deletion mutant,
even when TORC1 was active (absence of rapamycin). Con-
sistent with this observation, PKA-dependent phosphoryla-
tion of MAF1 was decreased in the sch9 mutant (Figure 5B).
Cells deleted for SCH9 also displayed constitutive nuclear
localization of the catalytic subunit TPK1 (Figure 5C). sch95A
mutant cells, in which all residues required for SCH9 phos-
phorylation and activation by TORC1 are mutated to ala-
nine, also displayed constitutive nuclear accumulation of
TPK1 (Figure 5C). Furthermore, in normal growth condi-
tions, sch9 deletion and sch95A mutants displayed constitu-
tive nuclear accumulation of the PKA target YAK1, similar
to what is observed in wild-type cells treated with rapamy-
cin (data not shown and Schmelzle et al., 2004). Together,
these observations suggest that TORC1 inhibits BCY1 T129
phosphorylation and TPK1 nuclear accumulation through
SCH9.
The MAP Kinase MPK1 Directly Phosphorylates BCY1
upon TORC1 Inhibition
The results described above suggested that, upon TORC1
inhibition, BCY1 is phosphorylated on T129 and thereby
activated. What is the T129 kinase that is inhibited by
TORC1? Two serine/threonine kinases, YAK1 and MCK1,
have been shown to mediate BCY1 phosphorylation upon
nutrient limitation or other stress (Werner-Washburne et al.,
1991; Grifﬁoen et al., 2001). YAK1 is activated upon TORC1
inhibition and antagonizes the PKA pathway (Zappacosta et
al., 2002; Martin et al., 2004; Deminoff et al., 2006). MCK1 is a
glycogen synthase kinase 3 (GSK3) homologue involved in
meiosis (Neigeborn and Mitchell, 1991; Kassir et al., 2006). In
mutants deleted for YAK1 or MCK1, rapamycin-induced
phosphorylation of BCY1 T129 was reduced but not abolished
(Supplementary Figures 5, A and B). In addition, YAK1 and
MCK1 puriﬁed from rapamycin-treated or -untreated yeast
cells failed to phosphorylate recombinant GST-BCY1 in vitro
(data not shown). These ﬁndings suggest that YAK1 and MCK1
may affect BCY1 phosphorylation but are not the kinases that
directly phosphorylate BCY1 T129 upon TORC1 inhibition.
Next, we examined BCY1 T129 phosphorylation in cells
lacking either NPR1 or SLT2/MPK1, two serine/threonine
kinases that are activated upon TORC1 inhibition (Schmidt
et al., 1998; Krause and Gray, 2002; Torres et al., 2002). NPR1
controls the sorting of several amino acid transporters in
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Figure 5. TORC1 inhibits MPK1 and BCY1 T129 phosphorylation
through the AGC kinase SCH9. (A) To follow the inﬂuence of SCH9
on BCY1 T129 and MPK1 phosphorylation, the yeast strains SA094
(WT) and SA135 (sch9) expressing HA-BCY1 were grown to expo-
nential phase and treated 45 min with rapamycin () or drug
vehicle () before total protein extraction. HA-BCY1 was immuno-
precipitated (IP) and analyzed by Western blot with anti-HA (HA-
BCY1) and anti-RxxS/T [BCY1-P (T129)] antibodies (IP panel). Total
(MPK1) and activated MPK1 (MPK1-P) were visualized in total cell
lysate by Western blot with the corresponding antibodies (panel
total). (B) Effect of SCH9 deletion on PKA-dependent phosphoryla-
tion of MAF1. The yeast strains SA148 (MAF1-HA SCH9) and SA232
(MAF1-HA sch9) were grown to exponential phase and treated for
30 min with rapamycin () or drug vehicle () before total protein
extraction. MAF1-HA was immunoprecipitated and analyzed by
Western blot with anti-HA [MAF1 (tot)] and anti-RRxS/T [MAF1-P
(PKA)] antibodies. For each condition, the phosphorylation at PKA
sites was quantiﬁed, normalized against the level of total protein,
and expressed as percentage [Phos/tot (%)]. (C) The rapamycin-
dependent localization of TPK1-HA (TPK1) was followed by immu-
noﬂuorescence of yeast strain SA20X carrying a plasmid expressing
wild-type SCH9 (WT  pJU675), no SCH9 (sch9  pRS416), or the
mutant sch9-5A (sch9-5A  pJU822). Cells were treated 30 min with
rapamycin () or drug vehicle (). TPK1-HA was localized by the
use of an anti-HA antibody. The nucleus was observed by DAPI
staining (DNA).
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Molecular Biology of the Cell 3482response to nutrients (Schmidt et al., 1998). Deletion of NPR1
had no effect on T129 phosphorylation upon rapamycin
treatment (Supplementary Figure 5C). The MAP kinase
MPK1 is part of the PKC1-BCK1-MKK1/2-MPK1 cascade
that regulates cell wall integrity and entry into quiescence in
response to stress (Levin, 2005). Deletion of MPK1 com-
pletely abolished rapamycin-induced T129 phosphorylation
(Figure 6A). To further investigate a role of MPK1 in BCY1
phosphorylation, we examined T129 phosphorylation in re-
sponse to conditions that activate the cell wall integrity
pathway. We activated the cell wall integrity pathway with
a genetically activated MAPKKK (BCK1-20 mutation) or
with chemicals such as SDS, Congo Red, and sodium or-
thovanadate that disrupt the cell wall. MPK1 activation was
monitored with an antibody that recognizes phosphorylated
p44/42 ERK MAPK but that also recognizes phosphorylated
MPK1 in yeast (Verna et al., 1997; Delley and Hall, 1999).
Like rapamycin treatment (Krause and Gray, 2002; Torres et
al., 2002 and Figure 6B), activation of the cell wall integrity
pathway stimulated both MPK1 and BCY1 T129 phosphor-
ylation (Figure 6B and Supplementary Figure 6C). We next
examined whether MPK1 immunopuriﬁed from rapamycin-
treated cells phosphorylates recombinant BCY1 in vitro. As
shown in Figure 6C, MPK1 puriﬁed from rapamycin-treated
cells indeed phosphorylated recombinant BCY1. Recombinant
BCY1 in which T129 was mutated to alanine was less phos-
phorylated compared with wild-type BCY1 (Supplementary
Figure 6E). These results suggest that MPK1 directly phosphor-
ylates BCY1 T129 upon TORC1 inhibition in vivo.
To investigate the physiological signiﬁcance of MPK1-
dependent BCY1 phosphorylation upon TORC1 inhibition,
we examined rapamycin-induced glycogen accumulation
and PKA-dependent phosphorylation of MAF1 and YPK3 in
cells lacking MPK1. Rapamycin-treated, MPK1-deleted cells
accumulated less glycogen than wild-type cells (Figure 6D).
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Figure 6. BCY1 T129 phosphorylation is me-
diated by activation of the MAP kinase
MPK1. (A) Yeast strains wild type (MPK1 
TB50a) or deleted (mpk1  TS45-1a) for MPK1
and expressing HA-BCY1 from a plasmid
(pTS137) were treated for 45 min with 200
ng/ml rapamycin () or drug vehicle ().
After protein extraction, HA-BCY1 was im-
munoprecipitated and analyzed by Western
blot using anti-HA (HA-BCY1), anti-RRxS/T
[BCY1-P (S145)], and anti-RxxS/T (BCY1-P
(T129)) antibodies. TB50a was used as a mock
control. (B) Total (HA-BCY1) and phospho-
T129 BCY1 [BCY1-P (T129)] were analyzed as
in A after 45-min treatment with rapamycin
(200 ng/ml), SDS (0.01%), or drug vehicle of
wild-type strain (WT  TB50a) or of a strain
expressing an hyperactive form of BCK1
(BCK1-20) from a plasmid (pRS316::BCK1-20;
panel IP). In parallel, total MPK1 (MPK1) and
active phosphorylated MPK1 (P-MPK1) were
analyzed by Western blot on the total extracts
used for HA-BCY1 IPs with the correspond-
ing antibodies (panel total). (C) In vitro kinase
assay. MPK1-HA was immunoprecipitated
from the yeast strain TS99-5c treated with
rapamycin () or drug vehicle () for 45 min.
The assay was performed as describe in Ma-
terials and Methods in presence of 1 go f
recombinant GST-BCY1 expressed from E.
coli. Total and phosphorylated proteins were
visualized by Coomassie staining (Coomas-
sie) and autoradiography (32P), respectively.
An aliquot of puriﬁed MPK1-HA was con-
served for analysis of total (MPK1) and acti-
vated MPK1 (MPK1-P) by Western blot as
above (WB). The level of BCY1 phosphoryla-
tion was quantiﬁed by densitometric analysis
(below panel 32P). MBP, a commonly used
MPK1 in vitro substrate, was used as a posi-
tive control (data not shown) (D) Glycogen
accumulation was tested by iodine staining
after 5-h rapamycin or drug vehicle treatment
of yeast strains wild type (WT  SA180) or
deleted for MPK1 (mpk1  SA183), for TOR1
(tor1  SA181), or for both genes (tor1 mpk1  SA185). (E) Effect of MPK1 deletion on PKA-dependent phosphorylation of MAF1. Yeast strains
containing MAF1-HA and expressing (MPK1; strain SA148) or lacking MPK1 (mpk1; strain SA233) were grown to exponential phase and
treated for the indicated time with rapamycin or drug vehicle before total protein extraction. MAF1-HA was immunoprecipitated and
analyzed by Western blot with anti-HA [MAF1 (tot)] and anti-RRxS/T (MAF1-P (PKA)) antibodies. MAF1 phosphorylation at PKA sites was
quantiﬁed as described in Figure 1 [Phos/tot (%)]. (F) Effect of MPK1 deletion on PKA-dependent phosphorylation of YPK3. Yeast strains
containing YPK3-HA and expressing (MPK1; strain SA234) or lacking MPK1 (mpk1; SA235) were analyzed as in E except that the cells were
treated with rapamycin () or drug vehicle () for 45 min.
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ished the hyperaccumulation of glycogen provoked by a
TOR1 deletion (Figure 6D). Conversely, and similar to rapa-
mycin treatment, activation of the cell wall integrity path-
way by SDS or caffeine (Levin, 2005) stimulated glycogen
accumulation (Supplementary Figure 6D). Furthermore, in
MPK1-deleted cells, phosphorylation of PKA sites in MAF1
and YPK3 was increased and rapamycin-induced dephos-
phorylation of these sites was reduced (Figure 6, E and F).
Thus, MPK1 appears to have a physiological role in TORC1-
mediated control of PKA.
Is SCH9 upstream of MPK1 in controlling phosphoryla-
tion of BCY1 T129, as expected from the above ﬁndings?
MPK1 was hyperphosphorylated in sch9 deletion and sch95A
mutants, even when TORC1 was active (absence of rapamy-
cin; Figure 5A and Supplementary Figure 6A). Furthermore,
sch9 deletion mutants displayed enhanced resistance to zy-
molyase, a cell wall–damaging agent (Supplementary Fig-
ure 6B), suggesting that the cell wall integrity pathway was
hyperactive in cells lacking SCH9. Thus, SCH9 appears to
negatively control both BCY1 T129 phosphorylation and
MPK1 activity, suggesting that SCH9 is indeed upstream of
MPK1 in controlling BCY1 T129 phosphorylation. The above
results taken together suggest that TORC1-SCH9 signaling
activates PKA (at least toward some substrates) by inhibit-
ing MPK1 direct phosphorylation of BCY1 T129.
DISCUSSION
To obtain insight into the shared regulation by PKA and
TORC1 (see Introduction), we investigated the TORC1 phos-
phoproteome. This revealed that PKA phosphorylation sites
are a primary target of TORC1, suggesting that TORC1 is an
upstream activator of PKA. However, many PKA sites were
not affected by TORC1, suggesting that TORC1 activates
PKA selectively rather than globally (see below). Thus, both
models that account for the shared regulation by TORC1
and PKA appear to be valid. First, TORC1 is an upstream
regulator of PKA toward some substrates, such as MAF1,
YPK3, and KSP1, whose phosphorylation by PKA is TORC1-
dependent. Second, TORC1 and PKA are in distinct but
parallel pathways that converge on common target proteins
or processes. This latter case includes proteins whose phos-
phorylation by PKA is not TORC1 dependent.
To investigate the molecular mechanism by which TORC1
controls PKA, we focused on the PKA negative regulatory
subunit BCY1. We found that TORC1 inhibits phosphoryla-
tion of T129 (and other sites) in BCY1. Phenotypes conferred
by mutation of T129 to phosphomimetic aspartate suggest
that T129 phosphorylation activates BCY1 and thereby inac-
tivates PKA. Furthermore, we found that TORC1 inhibits
BCY1 T129 phosphorylation by inhibiting the MAP kinase
MPK1. TORC1 inhibits MPK1 via the S6K ortholog SCH9.
Thus, we have deﬁned a pathway, consisting of TORC1-
SCH9-MPK1-BCY1-PKA, by which TORC1 prevents inacti-
vation of PKA. Although TORC1 phoshorylates and acti-
vates SCH9 directly and MPK1 phosphorylates (T129) and
activates BCY1 directly, it remains to be determined how
SCH9 inhibits phosphorylation and activation of MPK1 (see
below).
How could regulation of BCY1 by TORC1 control PKA
activity toward some but not all PKA substrates? On rapa-
mycin treatment, BCY1 sequesters PKA in the nucleus
(Schmelzle et al., 2004). This and our above ﬁndings suggest
that phosphorylated BCY1 (at T129 and likely other sites)
maintains PKA in the nucleus upon TORC1 inhibition and
may thus control access of PKA to speciﬁc substrates. This
control of PKA by BCY1 phosphorylation would be inde-
pendent of PKA control by binding of cAMP to BCY1.
This model is also supported by our observation that any
mutation that disrupts the BCY1-TPK1 interaction, e.g.,
BCY1S145D or TPK1T241A/D/E, prevents nuclear accumula-
tion of TPK1 upon rapamycin treatment (Supplementary
Figure 7 and data not shown). Finally, this model is similar
to a model proposed by Grifﬁoen et al. (2001, 2003), suggest-
ing that BCY1 phosphorylation upon glucose limitation con-
trols PKA localization and accessibility to substrates. An
alternative model is that T129-phosphorylated BCY1 binds
and inhibits only a speciﬁc pool of PKA. This separate pool
of PKA could be due to differential modiﬁcation or localiza-
tion of PKA by unknown factors. Different pools of PKA
might be in part explained by the fact that there are three
catalytic subunits of PKA (TPK1, TPK2, and TPK3) in yeast.
Conﬁrmation of the above or other possible models will
require further study.
Grifﬁoen et al. (2001, 2003) showed that BCY1 is phosphor-
ylated on two clusters of serines (CI and CII) in response to
stress. Here we identiﬁed, in addition to CI and CII, a third
cluster of serine and threonine residues (CIII) that are phos-
phorylated upon rapamycin treatment. T129 in CIII is an
important residue in the regulation of BCY1 and ultimately
PKA. However, the mild phenotypes conferred by mutation
of T129 to alanine or aspartate suggest that phosphorylation
at this residue is not the sole event regulating BCY1 and
PKA upon TORC1 inhibition. BCY1 is phosphorylated on at
least 16 serine or threonine residues other than T129, includ-
ing S74, S79, S83, T131, and S145. However, individual mu-
tation of S74, S79, and S83 and T131 had no phenotypic
consequence (data not shown). A phosphomimetic mutation
of S145 resulted in BCY1 inactivation, suggesting that phos-
phorylation of this site regulates BCY1, but the phosphory-
lation of S145 was independent of TORC1 (Supplementary
Figure 7). Further study will be required to determine the
roles and kinase(s) for all the phosphorylation sites in BCY1.
MPK1 is a MAP kinase in the PKC1/cell wall integrity
pathway that is activated in response to several stresses
including TORC1 inhibition (Krause and Gray, 2002; Torres
et al., 2002; Levin, 2005). Earlier studies have reported ge-
netic interactions between the cell wall integrity pathway
and the PKA pathway. For example, activation of the cell
wall integrity pathway suppresses the heat-shock sensitivity
caused by hyperactive RAS-cAMP signaling, and the RHO1
GDP/GTP exchange factor ROM2, which acts early in the
cell integrity pathway, is required for PKA-mediated stress
response (Verna et al., 1997; Park et al., 2005; Kuranda et al.,
2006). Our observation that MPK1 phosphorylates and acti-
vates BCY1 is consistent with the above genetic interactions.
Finally, we note that MPK1 is likely not the only kinase
involved in PKA regulation by TORC1, as rapamycin-in-
duced nuclear accumulation of PKA is not altered by loss of
MPK1 (whereas BCY1 phosphorylation is) or presence of
BCK1-20, a hyperactive MAPKKK BCK1 upstream of MPK1
(data not shown). Furthermore MPK1 deletion reduces but
does not abolish rapamycin-induced dephosphorylation of
MAF1 and YPK3.
TORC1 directly phosphorylates and activates the protein
kinase SCH9 (Urban et al., 2007). SCH9 was originally iden-
tiﬁed as a multicopy suppressor of a PKA defect (Toda et al.,
1988). Furthermore, SCH9 deletion severely decreases PKA-
dependent phosphorylation of MSN2 and MAF1 (Trott et al.,
2005; Huber et al., 2009; Lee et al., 2009). In agreement with
these previous observations, we ﬁnd that SCH9 acts down-
stream of TORC1 to maintain MPK1 inactive and PKA ac-
tive. The molecular link between SCH9 and MPK1 is likely
A. Soulard et al.
Molecular Biology of the Cell 3484indirect because MPK1 is phosphorylated and active when
SCH9 is inactive. The link between SCH9 and MPK1 may
involve ROM2. ROM2 was recently shown to interact genet-
ically with the TORC1, PKA, and cell wall integrity path-
ways (Park et al., 2005; Kuranda et al., 2006).
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